Department of Respiratory Care, Sichuan University West China Hospital, Chengdu, Sichuan, China.
Department of Critical Care Medicine, Sichuan University West China Hospital, Chengdu, Sichuan, China
BMJ Open. 2022 Oct 28;12(10):e056438. doi: 10.1136/bmjopen-2021-056438.
The incidence of postoperative pulmonary complications (PPCs) following thoracic surgery is high, which increases the mortality rate, prolongs the length of hospital stay and increases medical costs. Some studies have confirmed that preoperative risk assessment, intraoperative anaesthesia methods and intraoperative mechanical ventilation strategies, including recruitment manoeuvres (RMs), can reduce the incidence of PPCs. Despite these improved strategies, the incidence of PPCs remains high. However, mechanical ventilation strategies have not been studied in the postoperative period.
We assume that RM during mechanical ventilation with sequential high-flow nasal oxygen therapy (HFNO) after extubation can maintain the opening of the postoperative alveoli and ultimately reduce the incidence of PPCs after thoracic surgery. We will include thoracic surgery patients and divide them into the RM with sequential HFNO group and the control group. They will be given RMs and sequential HFNO or be given conventional treatment. The sample size is 654 adult patients (327 per group) undergone thoracic surgery and presenting to the intensive care unit.
This study was approved by the Biomedical Research Ethics Committee of West China Hospital of Sichuan University (REC2019-730). It is expected that this study will lead to a randomised controlled trial. We assume that the findings will provide more evidence about PPCs and improve the management of patients undergone thoracic surgery.
ChiCTR2100046356.
胸外科手术后肺部并发症(PPCs)的发生率较高,这会增加死亡率、延长住院时间并增加医疗费用。一些研究已经证实,术前风险评估、术中麻醉方法和术中机械通气策略,包括复张手法(RMs),可以降低 PPCs 的发生率。尽管这些改进策略已经得到了实施,但 PPCs 的发生率仍然很高。然而,机械通气策略在术后阶段并未得到研究。
我们假设,在拔管后序贯使用高流量鼻氧疗(HFNO)的机械通气过程中进行 RM,可以维持术后肺泡的开放,最终降低胸外科手术后 PPCs 的发生率。我们将纳入胸外科手术患者,并将其分为 RM 序贯 HFNO 组和对照组。他们将接受 RM 序贯 HFNO 或常规治疗。样本量为 654 名接受胸外科手术并入住重症监护病房的成年患者(每组 327 名)。
本研究已获得四川大学华西医院生物医学研究伦理委员会的批准(REC2019-730)。预计这项研究将开展一项随机对照试验。我们假设研究结果将提供更多关于 PPCs 的证据,并改善胸外科手术患者的管理。
ChiCTR2100046356。